Compare Abeona Therapeutics Inc (ABEO) vs iShares MSCI Singapore ETF (EWS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares MSCI Singapore ETF — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while iShares MSCI Singapore ETF trades at $31.06. The key difference: iShares MSCI Singapore ETF is trading nearer its 52-week high, Abeona Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | EWS | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $7.23 | $30.66 |
52-Week Low | $4.17 | $26.08 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
EWS, the iShares MSCI Singapore ETF, trades at $30.28, up 0.4% on the day, with a bullish technical signal driven by strong moving average alignment. The ETF offers a 3.97% dividend yield and is approaching its 2007 all-time high of $31.94, supported by Singapore's economic stability and financial sector strength. Recent news highlights focus on Singapore's AI initiatives and property market activity.
The outlook for EWS is positive, with potential upside to the $31.94 resistance level, but risks include concentrated holdings in financials and regional economic sensitivity. Investor sentiment is mixed, with some analysts advocating for diversification benefits while others caution on valuation after recent gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →
